Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) (original) (raw)

Abstract

Background: DMXAA (5,6-dimethylxanthenone-4-acetic acid) is a new drug synthesized in this laboratory and currently in phase I clinical trial. In mice it acts as an antivascular drug, selectively inhibiting tumour blood flow and inducing tumour haemorrhagic necrosis with resultant tumour regression. It also induces the synthesis of tumour necrosis factor (TNF), nitric oxide and serotonin. Cyproheptadine, a type 2 serotonin receptor antagonist, is known to reduce the degree of tumour necrosis-induced TNF in mice. We investigated the pharmacological interaction between a suboptimal dose of DMXAA (20 mg/kg) and cyproheptadine (20 mg/kg) using mice with Colon 38 tumours that are sensitive to DMXAA. Methods: Mice with or without tumours were treated with DMXAA and/or cyproheptadine. Concentrations of plasma and tissue DMXAA and the serotonin metabolite 5-hydroxyindoleacetic acid were measured by high performance liquid chromatography. TNF concentrations were measured by ELISA. Results: While DMXAA alone (20 mg/kg) showed little or no antitumour activity, coadministration with cyproheptadine was curative in four of five mice. DMXAA half-lives in plasma and tumour tissue were increased 5.1- and 5.6-fold, respectively, and the appearance of DMXAA glucuronides in bile was almost completely inhibited for up to 4 h. Serum TNF was low and unchanged by cyproheptadine, and plasma concentrations of the serotonin metabolite 5-hydroxyindoleacetic acid were also not substantially changed. Conclusion: The augmentation by cyproheptadine of the induction of tumour response to DMXAA reflects a pharmacological interaction, leading to increased plasma and tumour half-lives, and to reduced excretion. However, serum TNF concentrations were not increased, suggesting that the increased antitumour effects are mediated by an increased local tumour response, arising from the extended tumour DMXAA concentrations.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

  1. Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, New Zealand, , , , ,
    Liangli Zhao, Philip Kestell, Martin Philpott, Lai-Ming Ching, Li Zhuang & Bruce C. Baguley

Authors

  1. Liangli Zhao
    You can also search for this author inPubMed Google Scholar
  2. Philip Kestell
    You can also search for this author inPubMed Google Scholar
  3. Martin Philpott
    You can also search for this author inPubMed Google Scholar
  4. Lai-Ming Ching
    You can also search for this author inPubMed Google Scholar
  5. Li Zhuang
    You can also search for this author inPubMed Google Scholar
  6. Bruce C. Baguley
    You can also search for this author inPubMed Google Scholar

Additional information

Electronic Publication

Rights and permissions

About this article

Cite this article

Zhao, L., Kestell, P., Philpott, M. et al. Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).Cancer Chemother Pharmacol 47, 491–497 (2001). https://doi.org/10.1007/s002800000267

Download citation